Vivos

Acquisition Adds Complementary, Lower Cost Products for Treating Conditions Associated with Obstructive Sleep Apnea LITTLETON, Colo., March 01, 2023 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical…

LITTLETON, Colo., Feb. 21, 2023 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered…

Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements LITTLETON, Colo., January 20, 2023 -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing...

New capital extends cash runway as Vivos seeks to drive revenue growth and manage expenses in 2023 LITTLETON, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or...

Vivos Therapeutics Announces Pricing of $8 Million Private Placement LITTLETON, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company...

Approval represents third FDA clearance for Vivos’ oral appliances and first clearance specifically recognizing Vivos’ proprietary core technology LITTLETON Colorado, Jan. 04, 2023 Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ:...

Second and Third Quarter 10-Q Filings Bring Vivos Current on SEC Filings for Nasdaq Stock Market Purposes Management to Host Conference Call Today at 5:00 pm ET LITTLETON Colorado, Dec....